Prelude Therapeutics Inc PRLD
We take great care to ensure that the data presented and summarized in this overview for Prelude Therapeutics Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRLD
View all-
Orbimed Advisors LLC San Diego, CA10.9MShares$13.5 Million0.53% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$12.6 Million0.22% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$4.67 Million0.14% of portfolio
-
Boxer Capital, LLC San Diego, CA1.71MShares$2.12 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.1MShares$1.36 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.02MShares$1.27 Million0.0% of portfolio
-
Exodus Point Capital Management, LP New York, NY922KShares$1.14 Million0.01% of portfolio
-
Avidity Partners Management LP Dallas, TX890KShares$1.1 Million0.11% of portfolio
-
Massachusetts Financial Services CO Boston, MA550KShares$681,4170.0% of portfolio
Latest Institutional Activity in PRLD
Top Purchases
Top Sells
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Insider Transactions at PRLD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
Bryant David Lim CLO, Interim CFO, Corp Sec. |
BUY
Open market or private purchase
|
Direct |
25,000
+47.71%
|
$0
$0.91 P/Share
|
|
Dec 19
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
6,888
+5.12%
|
$0
$0.89 P/Share
|
|
Dec 18
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+7.89%
|
$0
$0.93 P/Share
|
|
Oct 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,349
-5.02%
|
$6,698
$2.0 P/Share
|
|
Oct 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+12.33%
|
-
|
|
Jul 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,347
-5.52%
|
$10,041
$3.6 P/Share
|
|
Jul 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+13.39%
|
-
|
|
Apr 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,347
-6.13%
|
$13,388
$4.74 P/Share
|
|
Apr 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+14.65%
|
-
|
|
Jan 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,844
-7.83%
|
$11,532
$3.77 P/Share
|
|
Jan 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+16.03%
|
-
|
|
Oct 04
2023
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+19.09%
|
-
|
|
Jul 04
2023
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,242
-9.65%
|
$12,968
$4.65 P/Share
|
|
Jul 04
2023
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+21.82%
|
-
|
|
May 25
2023
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
900
+0.08%
|
$4,500
$5.31 P/Share
|
|
May 24
2023
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.09%
|
$5,000
$5.01 P/Share
|
|
May 24
2023
|
Bryant David Lim CLO, Interim CFO, Corp Sec. |
BUY
Open market or private purchase
|
Direct |
2,400
+50.0%
|
$12,000
$5.39 P/Share
|
|
May 23
2023
|
Laurent Chardonnet Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+10.6%
|
$25,000
$5.5 P/Share
|
|
May 23
2023
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
11,856
+1.1%
|
$59,280
$5.63 P/Share
|
|
May 22
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
869,565
+7.91%
|
$4,347,825
$5.75 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 132K shares |
|---|---|
| Exercise of conversion of derivative security | 37.5K shares |
| Payment of exercise price or tax liability | 13.9K shares |
|---|